Followers | 839 |
Posts | 120502 |
Boards Moderated | 18 |
Alias Born | 09/05/2002 |
Thursday, December 23, 2021 9:54:33 AM
https://www.prnewswire.com/news-releases/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-for-treatment-of-covid-19-in-certain-adults-301450419.html
The limitation is warranted, IMO, in light of Molnupiravir’s weak efficacy and questionable safety.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Recent MRK News
- Merck to Present New Long-Term Data for Tulisokibart (MK-7240), an Investigational Anti-TL1A Monoclonal Antibody, in Inflammatory Bowel Disease at UEG Week 2024 • Business Wire • 09/26/2024 10:45:00 AM
- Merck Provides Update on Phase 3 KEYFORM-007 Trial Evaluating Investigational Fixed-Dose Combination of Favezelimab and Pembrolizumab for Patients With Previously Treated PD-L1 Positive Microsatellite Stable Metastatic Colorectal Cancer • Business Wire • 09/25/2024 10:45:00 AM
- Merck’s KEYTRUDA® (pembrolizumab) Receives New Approvals in Japan for Certain Patients With Non-Small Cell Lung Carcinoma (NSCLC) and Radically Unresectable Urothelial Carcinoma • Business Wire • 09/25/2024 10:30:00 AM
- Merck Animal Health Announces Expansion of NOBIVAC® NXT Platform with the First and Only RNA-Particle Technology Vaccine for Feline Leukemia Virus • Business Wire • 09/24/2024 12:06:00 PM
- Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers • Business Wire • 09/20/2024 11:30:00 AM
- FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM) • Business Wire • 09/18/2024 10:45:00 AM
- Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Doublet Chemotherapy in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer in HERTHENA-Lung02 Phase 3 Trial • Business Wire • 09/17/2024 10:00:00 AM
- BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024 • GlobeNewswire Inc. • 09/16/2024 11:00:00 AM
- KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by More Than One-Third (34%) Versus Neoadjuvant Chemotherapy in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC) • Business Wire • 09/15/2024 02:30:00 PM
- Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma • Business Wire • 09/15/2024 12:45:00 PM
- KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma • Business Wire • 09/14/2024 02:35:00 PM
- Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Reduced Risk of Death by 33% Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer • Business Wire • 09/14/2024 02:30:00 PM
- KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Overall Survival (OS) Versus Trastuzumab and Chemotherapy Alone in First-Line Treatment of Patients With HER2-Positive Advanced Gastric or GEJ Adenocarcinoma • Business Wire • 09/14/2024 07:15:00 AM
- Santé Canada approuve KEYTRUDA® pour le traitement, en monothérapie, des adultes et des enfants atteints d'une tumeur solide non résécable ou métastatique associée à une forte instabilité microsatellitaire (IMS) ou à une déficience du système d • PR Newswire (Canada) • 09/12/2024 11:00:00 AM
- Health Canada Approves KEYTRUDA® as monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumours that have progressed following prio • PR Newswire (Canada) • 09/12/2024 11:00:00 AM
- Merck to Participate in the Bank of America 2024 Global Healthcare Conference • Business Wire • 09/11/2024 10:45:00 AM
- Merck Announces Positive Top-line Results from Phase 3 Trial Evaluating Efficacy and Safety of GARDASIL®9 in Japanese Males • Business Wire • 09/11/2024 10:30:00 AM
- Junior Biotech Utilizes AI To Shorten Drug Discovery Timelines, Ultimately Saving Lives • AllPennyStocks.com • 09/10/2024 10:53:00 PM
- Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial • Business Wire • 09/07/2024 03:30:00 PM
- Merck Canada et l'Alliance pharmaceutique pancanadienne (APP) concluent avec succès les négociations relatives à WELIREG® (belzutifan) • PR Newswire (Canada) • 09/05/2024 11:00:00 AM
- Merck Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for WELIREG® (belzutifan) • PR Newswire (Canada) • 09/05/2024 11:00:00 AM
- L'utilisation de WINREVAIR® (sotatercept) est maintenant autorisée au Canada pour les adultes atteints d'hypertension artérielle pulmonaire • PR Newswire (Canada) • 09/04/2024 07:00:00 PM
- WINREVAIR® (sotatercept) is now authorized for use in Canada for Adults with Pulmonary Arterial Hypertension • PR Newswire (Canada) • 09/04/2024 07:00:00 PM
- Merck to Present Survival Data and New Research on 10 Investigational or Approved Medicines at ESMO Congress 2024 • Business Wire • 09/04/2024 10:45:00 AM
- Merck and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret™ for the Treatment of Diabetic Macular Edema • Business Wire • 09/04/2024 10:40:00 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM